Arimidex Observational: Reason for and Effect of Change From Tamoxifen
ARREST
Arimidex: Reason for and Effect of Change From Tamoxifen
2 other identifiers
observational
200
1 country
33
Brief Summary
The purpose of this study is to analyse the effect on quality of life after 3 months of treatment after changing adjuvant therapy from tamoxifen to Arimidex.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
33 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 1, 2004
CompletedFirst Submitted
Initial submission to the registry
October 31, 2005
CompletedFirst Posted
Study publicly available on registry
November 1, 2005
CompletedOctober 12, 2007
June 1, 2007
October 31, 2005
October 11, 2007
Conditions
Keywords
Eligibility Criteria
You may qualify if:
- Postmenopausal
- Hormone sensitive breast cancer
- Patient uses tamoxifen or has stopped taking tamoxifen less than 7 days ago
You may not qualify if:
- Visceral metastases
- Patients with signs of progression at the moment of changing therapy
- Patients who have used other endocrine treatments for breast cancer besides tamoxifen
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- AstraZenecalead
Study Sites (33)
Research Site
's-Hertogenbosch, Netherlands
Research Site
Alkmaar, Netherlands
Research Site
Antwerpen, Netherlands
Research Site
Apeldoorn, Netherlands
Research Site
Bergen op Zoom, Netherlands
Research Site
Boxmeer, Netherlands
Research Site
Breda, Netherlands
Research Site
Doetinchem, Netherlands
Research SIte
Dordrecht, Netherlands
Research Site
Ede, Netherlands
Research Site
Eindhoven, Netherlands
Research Site
Enschede, Netherlands
Research Site
Flushing, Netherlands
Research Site
Geldrop, Netherlands
Research Site
Groningen, Netherlands
Research Site
Harderwijk, Netherlands
Research Site
Helmond, Netherlands
Research Site
Hoogeveen, Netherlands
Research Site
Hoorn, Netherlands
Research Site
Leiden, Netherlands
Research Site
Oosterhout, Netherlands
Research Site
Purmerend, Netherlands
Research Site
Roermond, Netherlands
Research Site
Roosendaal, Netherlands
Research Site
Rotterdam, Netherlands
Research Site
Schiedam, Netherlands
Research Site
Terneuzen, Netherlands
Research Site
The Hague, Netherlands
Research Site
Tiel, Netherlands
Research Site
Venray, Netherlands
Research Site
Winterswijk, Netherlands
Research Site
Zoetermeer, Netherlands
Research Site
Zutphen, Netherlands
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
AstraZeneca The Netherlands Medical Director, MD
AstraZeneca
Study Design
- Study Type
- observational
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
October 31, 2005
First Posted
November 1, 2005
Study Start
July 1, 2004
Last Updated
October 12, 2007
Record last verified: 2007-06